Number of the records: 1
1,3-Butadiene: Biomarkers and application to risk assessment
- 1.
SYSNO ASEP 0350229 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title 1,3-Butadiene: Biomarkers and application to risk assessment Author(s) Swenberg, J. A. (US)
Bordeerat, N. K. (US)
Boysen, G. (US)
Carro, S. (US)
Georgieva, N. I. (US)
Troutman, J. M. (US)
Upton, P. B. (US)
Albertini, R. J. (US)
Vacek, P. M. (US)
Walker, V. E. (US)
Šrám, Radim (UEM-P) RID
Goggin, M. (US)
Tretyakova, N. (US)Source Title Chemico-Biological Interactions. - : Elsevier - ISSN 0009-2797
Roč. 192, 1-2 (2011), s. 150-154Number of pages 5 s. Language eng - English Country IE - Ireland Keywords risk assessment ; 1,3-butadiene ; occupational exposure Subject RIV DN - Health Impact of the Environment Quality CEZ AV0Z50390512 - UEM-P (2005-2011) UT WOS 000292435100026 EID SCOPUS 79958022697 DOI 10.1016/j.cbi.2010.10.010 Annotation 1,3-Butadiene (BD) is a known human carcinogen that is metabolized mainly by P450 2E1 to three epoxides (EB, DEB and EB-diol). These epoxides vary in their mutagenic potency, with DEB being the most mutagenic metabolite. It is important to understand the internal formation of the individual epoxides to assign the relative risk for each metabolite and to understand the molecular mechanisms responsible for differences in carcinogenicity. In the extensive exposure-biomarker studies on mice, rats and humans was found that using low exposures that range from current occupational levels to human exposures from tobacco smoke mice are very different from humans, with mice forming 200 times more DEB than humans at exposures of 0.1-1.5ppm BD. These data provide a scientific basis for improved risk assessment of BD. Workplace Institute of Experimental Medicine Contact Lenka Koželská, lenka.kozelska@iem.cas.cz, Tel.: 241 062 218, 296 442 218 Year of Publishing 2012
Number of the records: 1